Increased Level of Systolic Blood Pressure in Hepatocellular Carcinoma Patients with Diabetes Mellitus.
diabetes mellitus
hepatocellular carcinoma
systolic blood pressure
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
02
2020
accepted:
12
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
More than 50% of patients with type 2 diabetes mellitus (DM) also have hypertension. Moreover, hypertension has been regarded as one paraneoplastic phenomenon of hepatocellular carcinoma (HCC). Our study was designed to determine the relationship between blood pressure and DM in HCC patients. A total of 879 HCC patients were included and 151 (17.2%) were diagnosed with DM. Multivariable logistic regression analysis was used to determine the relationship and the results were expressed as adjusted odds ratios (AORs) and their 95% confidence intervals (CIs). Considering the effect of potential confounders, sub-group analysis was performed. We would further study the association of systolic blood pressure (SBP) with fasting glucose, and the association between DM duration/treatment and SBP level. Compared with non-diabetic patients, the diabetic patients had increased levels of SBP (133.7±18.5 mmHg vs 128.3±15.2 mmHg, P=0.001) and fasting blood glucose (9.13±3.04 mmol/L vs 5.18±1.08 mmol/L, P<0.001), an elder age (58.5±10.2 years vs 55.3±11.2 years, P=0.001), a higher percentage of cirrhosis diagnosis (60.9% vs 48.2%, P=0.004), lower percentages of drinking (18.5% vs 30.8%, P=0.002) and smoking (30.5% vs 43.7%, P=0.003), and decreased levels of GGT (median/interquartile-range 88/53-177 U/L vs 117/58-248 U/L, P=0.037), platelet count (121.4±76.6 ×10 SBP level was increased in HCC patients with diabetes mellitus.
Sections du résumé
BACKGROUND
BACKGROUND
More than 50% of patients with type 2 diabetes mellitus (DM) also have hypertension. Moreover, hypertension has been regarded as one paraneoplastic phenomenon of hepatocellular carcinoma (HCC). Our study was designed to determine the relationship between blood pressure and DM in HCC patients.
PATIENTS AND METHODS
METHODS
A total of 879 HCC patients were included and 151 (17.2%) were diagnosed with DM. Multivariable logistic regression analysis was used to determine the relationship and the results were expressed as adjusted odds ratios (AORs) and their 95% confidence intervals (CIs). Considering the effect of potential confounders, sub-group analysis was performed. We would further study the association of systolic blood pressure (SBP) with fasting glucose, and the association between DM duration/treatment and SBP level.
RESULTS
RESULTS
Compared with non-diabetic patients, the diabetic patients had increased levels of SBP (133.7±18.5 mmHg vs 128.3±15.2 mmHg, P=0.001) and fasting blood glucose (9.13±3.04 mmol/L vs 5.18±1.08 mmol/L, P<0.001), an elder age (58.5±10.2 years vs 55.3±11.2 years, P=0.001), a higher percentage of cirrhosis diagnosis (60.9% vs 48.2%, P=0.004), lower percentages of drinking (18.5% vs 30.8%, P=0.002) and smoking (30.5% vs 43.7%, P=0.003), and decreased levels of GGT (median/interquartile-range 88/53-177 U/L vs 117/58-248 U/L, P=0.037), platelet count (121.4±76.6 ×10
CONCLUSION
CONCLUSIONS
SBP level was increased in HCC patients with diabetes mellitus.
Identifiants
pubmed: 32606857
doi: 10.2147/DMSO.S251943
pii: 251943
pmc: PMC7304669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1979-1988Informations de copyright
© 2020 Zhang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
World J Hepatol. 2016 Sep 28;8(27):1119-1127
pubmed: 27721917
Diabetes Care. 2012 Jan;35 Suppl 1:S64-71
pubmed: 22187472
Cardiovasc Diabetol. 2020 May 2;19(1):50
pubmed: 32359350
Acta Diabetol. 2005 Apr;42 Suppl 1:S17-25
pubmed: 15868115
Aliment Pharmacol Ther. 2020 Jan;51(1):78-89
pubmed: 31747082
Environ Health Prev Med. 2012 Jul;17(4):285-91
pubmed: 22065307
J Hepatocell Carcinoma. 2019 Jul 11;6:105-117
pubmed: 31372364
J Gastroenterol. 1999 Aug;34(4):530-4
pubmed: 10452690
Diabetes Care. 2003 Jan;26 Suppl 1:S80-2
pubmed: 12502624
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
Hepatobiliary Pancreat Dis Int. 2013 Aug;12(4):385-93
pubmed: 23924496
Arch Intern Med. 1989 Sep;149(9):2111-3
pubmed: 2549897
Hypertens Res. 2017 Jul;40(7):710-716
pubmed: 28250411
Diabetes Ther. 2017 Oct;8(5):981-989
pubmed: 28929319
Dig Dis Sci. 2016 Feb;61(2):636-45
pubmed: 26703125
BMJ Open Diabetes Res Care. 2016 Oct 10;4(1):e000285
pubmed: 27843555
Int J Cancer. 2012 Apr 1;130(7):1639-48
pubmed: 21544812
Maturitas. 2017 Oct;104:11-18
pubmed: 28923170
World J Gastroenterol. 2013 Apr 21;19(15):2395-403
pubmed: 23613635
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Am J Gastroenterol. 2004 Aug;99(8):1479-87
pubmed: 15307864
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
World J Gastroenterol. 2010 Sep 21;16(35):4467-75
pubmed: 20845516
BMC Cardiovasc Disord. 2017 Jul 27;17(1):206
pubmed: 28750662
Hepatobiliary Pancreat Dis Int. 2009 Oct;8(5):465-73
pubmed: 19822488
Int J Cardiol. 2013 Oct 3;168(3):2979-81
pubmed: 23659881
Diabetes Care. 2017 Sep;40(9):1273-1284
pubmed: 28830958